Physician profile
Aimee Bert-Moreno
NPI 1215518345
$5,687.84
in general payments reported to CMS, 2019-2025
26 companies · $796 in 2025
The $796 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $1,948 · 2023: $1,158 · 2024: $1,215 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,168.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,416.90 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $883.94 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $414.17 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbvie INC. | $219.38 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.20 | 2022-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $216.93 | 2022-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $206.78 | 2022-2024 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $203.84 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $152.35 | 2022-2024 | Contrave, Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $113.36 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $98.81 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $95.82 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $79.11 | 2023-2025 | |
| Amgen INC. | $52.24 | 2021-2023 | Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $43.00 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.92 | 2022 | |
| Vivus LLC | $41.47 | 2022 | |
| Esperion Therapeutics, INC. | $32.24 | 2021-2024 | Nexletol |
| Daiichi Sankyo INC. | $31.95 | 2022 | |
| Sumitomo Pharma America, INC. | $25.82 | 2024 | Gemtesa |
| Grt US Holding, INC. | $20.74 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.31 | 2022 | |
| Glaxosmithkline, LLC. | $17.07 | 2024 | Shingrix |
| Acerus Pharmaceuticals Corporation | $16.39 | 2022 | |
| Antares Pharma, INC. | $13.63 | 2022 | |
| Dynavax Technologies Corporation | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Bert-Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.